Prediction of adverse effects of doxorubicin based on pharmacokinetics and pharmacogenetics in patients with breast cancer
Treatment with doxorubicin for breast cancer is frequently associated with various adverse effects that can be related to the drug plasma concentration. The latter may be modified by pharmacogenetic factors.
Authors
- E.V. Shikh
- Р. Е. Казаков (ORCID: https://orcid.org/0000-0003-0802-4229)
- Drozdov Vn (ORCID: https://orcid.org/0000-0002-0535-2916)
- Alina A. Bagdasaryan (ORCID: https://orcid.org/0000-0003-3994-8766)
- Smirnov Vv (ORCID: https://orcid.org/0000-0002-8232-6682)
Publication Details
- Journal
- Clinical pharmacology and therapy
- Published
- 2024-08-25
- DOI
- https://doi.org/10.32756/0869-5490-2024-3-21-25
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00